(1 - 7 von 7
)
Angle PLC: Parsortix enables CTC molecular characterisation
www.finanznachrichten.de
Professor Robert Zeillinger, Head of the Molecular Oncology Group at the Medical University of Vienna, commented: "In the study we have demonstrated that ANGLE's Parsortix™ system addresses key ...
News Article - DDNewswww.ddn-news.com › ...
www.drugdiscoverynews.com
Robert Zeillinger, head of the Molecular Oncology Group, and Dr. Eva Obermayr, principal investigator, sought to develop a protocol that combined the ...
Researchers successfully use Parsortix system in ovarian cancer drug...
medicalxpress.com
Robert Zeillinger, Head of the Molecular Oncology Group at the Medical University of Vienna. 'This opens up completely new approaches to ...
sortiert nach Relevanz / Datum